Overview

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Status:
Completed
Trial end date:
2018-08-10
Target enrollment:
Participant gender:
Summary
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab